Pharming receives Orphan Drug Designation from the European Commission for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)

With no currently approved treatment, leniolisib has the potential to address a significant unmet need for patients with APDS. — Sijmen de Vries - CEO Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗